FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2155278324> ?p ?o ?g. }

• W2155278324 endingPage "2138" @default.
• W2155278324 startingPage "2130" @default.
• W2155278324 abstract "Purpose To investigate genetic alterations in lacrimal gland adenoid cystic carcinomas (ACCs) with emphasis on the MYB-NFIB fusion oncogene and its downstream targets, MYB rearrangements, and copy number alterations in relation to clinical data and survival. Design Experimental study. Participants and Controls Fourteen patients with primary lacrimal gland ACC were included. As a control, we also studied the expression of MYB-NFIB in 19 non-ACC lacrimal gland tumors. Methods The expression and identity of MYB-NFIB fusion transcripts were studied using reverse transcriptase polymerase chain reaction (RT-PCR) and nucleotide sequence analyses. Quantitative polymerase chain reaction (PCR) and immunohistochemistry were used to evaluate the expression of MYB/MYB-NFIB target genes. High-resolution array-based comparative genomic hybridization (arrayCGH) and fluorescence in situ hybridization were used to study copy number alterations and MYB rearrangements. Main Outcome Measures mRNA or protein expression of MYB-NFIB, MYB, and its down stream targets; copy number alterations; and genomic rearrangements. Results The median age of the patients was 43 years (equal gender distribution), and the median time of survival was 8.6 years. The MYB-NFIB fusion was expressed in 7 of 14 ACCs. In contrast, all non-ACC tumors were fusion-negative. All 13 ACCs tested stained positive for the MYB protein, and for the MYB targets KIT and BCL2, 12 were positive for MYC and CCNE1, and 9 were positive for CCNB1. Rearrangements of MYB were detected in 8 of 13 cases, including 2 cases with gain of an apparently intact MYB gene. The arrayCGH analysis revealed recurrent copy number alterations with losses involving 6q23-q27, 12q12-q14.1, and 17p13.3-p12, and gains involving 19q12, 19q13.31-qter, 8q24.13-q24.21, 11q12.3-q14.1, and 6q23.3. Neither MYB-NFIB fusion nor any copy number alteration correlated with survival. Conclusions Lacrimal gland ACCs are frequently positive for the MYB-NFIB fusion, overexpress MYB and its downstream targets, and have genomic profiles characterized by losses involving 6q, 12q, and 17p, and gains involving 19q, 8q, and 11q. Our findings show that lacrimal gland ACCs are genetically and clinically similar to their salivary gland counterparts and that MYB-NFIB is a clinically useful diagnostic biomarker for ACC. Our data also suggest that MYB and its downstream targets are potential therapeutic targets for these tumors. Financial Disclosure(s) The author(s) have no proprietary or commercial interest in any materials discussed in this article. To investigate genetic alterations in lacrimal gland adenoid cystic carcinomas (ACCs) with emphasis on the MYB-NFIB fusion oncogene and its downstream targets, MYB rearrangements, and copy number alterations in relation to clinical data and survival. Experimental study. Fourteen patients with primary lacrimal gland ACC were included. As a control, we also studied the expression of MYB-NFIB in 19 non-ACC lacrimal gland tumors. The expression and identity of MYB-NFIB fusion transcripts were studied using reverse transcriptase polymerase chain reaction (RT-PCR) and nucleotide sequence analyses. Quantitative polymerase chain reaction (PCR) and immunohistochemistry were used to evaluate the expression of MYB/MYB-NFIB target genes. High-resolution array-based comparative genomic hybridization (arrayCGH) and fluorescence in situ hybridization were used to study copy number alterations and MYB rearrangements. mRNA or protein expression of MYB-NFIB, MYB, and its down stream targets; copy number alterations; and genomic rearrangements. The median age of the patients was 43 years (equal gender distribution), and the median time of survival was 8.6 years. The MYB-NFIB fusion was expressed in 7 of 14 ACCs. In contrast, all non-ACC tumors were fusion-negative. All 13 ACCs tested stained positive for the MYB protein, and for the MYB targets KIT and BCL2, 12 were positive for MYC and CCNE1, and 9 were positive for CCNB1. Rearrangements of MYB were detected in 8 of 13 cases, including 2 cases with gain of an apparently intact MYB gene. The arrayCGH analysis revealed recurrent copy number alterations with losses involving 6q23-q27, 12q12-q14.1, and 17p13.3-p12, and gains involving 19q12, 19q13.31-qter, 8q24.13-q24.21, 11q12.3-q14.1, and 6q23.3. Neither MYB-NFIB fusion nor any copy number alteration correlated with survival. Lacrimal gland ACCs are frequently positive for the MYB-NFIB fusion, overexpress MYB and its downstream targets, and have genomic profiles characterized by losses involving 6q, 12q, and 17p, and gains involving 19q, 8q, and 11q. Our findings show that lacrimal gland ACCs are genetically and clinically similar to their salivary gland counterparts and that MYB-NFIB is a clinically useful diagnostic biomarker for ACC. Our data also suggest that MYB and its downstream targets are potential therapeutic targets for these tumors." @default.
• W2155278324 created "2016-06-24" @default.
• W2155278324 creator A5001567432 @default.
• W2155278324 creator A5002049307 @default.
• W2155278324 creator A5038440788 @default.
• W2155278324 creator A5058122841 @default.
• W2155278324 creator A5071679787 @default.
• W2155278324 creator A5076560068 @default.
• W2155278324 creator A5091658472 @default.
• W2155278324 date "2013-10-01" @default.
• W2155278324 modified "2023-10-16" @default.
• W2155278324 title "Adenoid Cystic Carcinoma of the Lacrimal Gland: MYB Gene Activation, Genomic Imbalances, and Clinical Characteristics" @default.
• W2155278324 cites W1536156148 @default.
• W2155278324 cites W1650797637 @default.
• W2155278324 cites W1972121227 @default.
• W2155278324 cites W1974202442 @default.
• W2155278324 cites W1975532682 @default.
• W2155278324 cites W1990526751 @default.
• W2155278324 cites W1998349351 @default.
• W2155278324 cites W2000161070 @default.
• W2155278324 cites W2003477566 @default.
• W2155278324 cites W2006711712 @default.
• W2155278324 cites W2006796890 @default.
• W2155278324 cites W2007625022 @default.
• W2155278324 cites W2009500653 @default.
• W2155278324 cites W2025105993 @default.
• W2155278324 cites W2027260180 @default.
• W2155278324 cites W2032339782 @default.
• W2155278324 cites W2035799305 @default.
• W2155278324 cites W2037532322 @default.
• W2155278324 cites W2041921202 @default.
• W2155278324 cites W2048105337 @default.
• W2155278324 cites W2049904360 @default.
• W2155278324 cites W2050963209 @default.
• W2155278324 cites W2052608331 @default.
• W2155278324 cites W2057983896 @default.
• W2155278324 cites W2061308322 @default.
• W2155278324 cites W2073482997 @default.
• W2155278324 cites W2075751643 @default.
• W2155278324 cites W2081373862 @default.
• W2155278324 cites W2084370215 @default.
• W2155278324 cites W2085043050 @default.
• W2155278324 cites W2086168468 @default.
• W2155278324 cites W2104475595 @default.
• W2155278324 cites W2107277218 @default.
• W2155278324 cites W2112487172 @default.
• W2155278324 cites W2116753165 @default.
• W2155278324 cites W2117731452 @default.
• W2155278324 cites W2119909954 @default.
• W2155278324 cites W2134273037 @default.
• W2155278324 cites W2135067095 @default.
• W2155278324 cites W2138366746 @default.
• W2155278324 cites W2143500395 @default.
• W2155278324 cites W2151969179 @default.
• W2155278324 cites W2330379514 @default.
• W2155278324 cites W2332011590 @default.
• W2155278324 cites W4248057491 @default.
• W2155278324 cites W4248622847 @default.
• W2155278324 doi "https://doi.org/10.1016/j.ophtha.2013.03.030" @default.
• W2155278324 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23725736" @default.
• W2155278324 hasPublicationYear "2013" @default.
• W2155278324 type Work @default.
• W2155278324 sameAs 2155278324 @default.
• W2155278324 citedByCount "56" @default.
• W2155278324 countsByYear W21552783242013 @default.
• W2155278324 countsByYear W21552783242014 @default.
• W2155278324 countsByYear W21552783242015 @default.
• W2155278324 countsByYear W21552783242016 @default.
• W2155278324 countsByYear W21552783242017 @default.
• W2155278324 countsByYear W21552783242018 @default.
• W2155278324 countsByYear W21552783242019 @default.
• W2155278324 countsByYear W21552783242020 @default.
• W2155278324 countsByYear W21552783242021 @default.
• W2155278324 countsByYear W21552783242022 @default.
• W2155278324 countsByYear W21552783242023 @default.
• W2155278324 crossrefType "journal-article" @default.
• W2155278324 hasAuthorship W2155278324A5001567432 @default.
• W2155278324 hasAuthorship W2155278324A5002049307 @default.
• W2155278324 hasAuthorship W2155278324A5038440788 @default.
• W2155278324 hasAuthorship W2155278324A5058122841 @default.
• W2155278324 hasAuthorship W2155278324A5071679787 @default.
• W2155278324 hasAuthorship W2155278324A5076560068 @default.
• W2155278324 hasAuthorship W2155278324A5091658472 @default.
• W2155278324 hasConcept C104317684 @default.
• W2155278324 hasConcept C111829193 @default.
• W2155278324 hasConcept C142724271 @default.
• W2155278324 hasConcept C150194340 @default.
• W2155278324 hasConcept C2777542201 @default.
• W2155278324 hasConcept C2777546739 @default.
• W2155278324 hasConcept C2779231225 @default.
• W2155278324 hasConcept C30481170 @default.
• W2155278324 hasConcept C502942594 @default.
• W2155278324 hasConcept C54355233 @default.
• W2155278324 hasConcept C62794011 @default.
• W2155278324 hasConcept C71924100 @default.
• W2155278324 hasConcept C86803240 @default.
• W2155278324 hasConceptScore W2155278324C104317684 @default.
• W2155278324 hasConceptScore W2155278324C111829193 @default.

• next